Ibudilast attenuates alcohol cue-elicited frontostriatal functional connectivity in alcohol use disorder.

ABSTRACT:

Background

Ibudilast, a novel neuroimmune modulator being studied to treat alcohol use disorder (AUD), was shown in a randomized controlled trial (NCT03489850) to reduce ventral striatum (VS) activation in response to visual alcohol cues. The present study extended this finding by probing the effects of ibudilast on alcohol cue-elicited functional connectivity (i.e., temporally correlated activation) with the VS seed. The study also tests the association between functional connectivity and alcohol use during the trial.

Methods

Non-treatment-seeking participants (n = 45) with current alcohol use disorder were randomized to receive twice-daily dosing with either ibudilast (50 mg; n = 20) or placebo (n = 25). Upon reaching the target dosagee of the medication or placebo, partic

SUBMITTER: Burnette EM 

PROVIDER: S-EPMC8602728 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature